Shire PLC (SHPG) Shares Bought by Ngam Advisors L.P.
Ngam Advisors L.P. raised its position in Shire PLC (NASDAQ:SHPG) by 17.0% during the third quarter, according to its most recent filing with the SEC. The firm owned 48,087 shares of the biopharmaceutical company’s stock after buying an additional 7,003 shares during the period. Ngam Advisors L.P.’s holdings in Shire PLC were worth $9,322,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. Lone Pine Capital LLC purchased a new position in shares of Shire PLC during the second quarter worth about $465,566,000. Capital World Investors purchased a new position in shares of Shire PLC during the second quarter worth about $285,568,000. Vanguard Group Inc. purchased a new position in shares of Shire PLC during the second quarter worth about $278,421,000. FMR LLC boosted its position in shares of Shire PLC by 86.7% in the second quarter. FMR LLC now owns 2,663,506 shares of the biopharmaceutical company’s stock worth $490,297,000 after buying an additional 1,237,100 shares in the last quarter. Finally, Marshall Wace LLP boosted its position in shares of Shire PLC by 3,498.9% in the second quarter. Marshall Wace LLP now owns 1,055,873 shares of the biopharmaceutical company’s stock worth $194,365,000 after buying an additional 1,026,534 shares in the last quarter. Hedge funds and other institutional investors own 22.78% of the company’s stock.
Shares of Shire PLC (NASDAQ:SHPG) traded up 1.02% during trading on Tuesday, hitting $176.62. The company had a trading volume of 433,836 shares. The firm’s 50 day moving average is $179.87 and its 200-day moving average is $187.59. Shire PLC has a 52 week low of $147.60 and a 52 week high of $215.05. The stock has a market capitalization of $52.61 billion, a P/E ratio of 36.70 and a beta of 1.46.
Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings results on Tuesday, November 1st. The biopharmaceutical company reported $3.17 EPS for the quarter, missing analysts’ consensus estimates of $3.21 by $0.04. The company earned $3.45 billion during the quarter, compared to analysts’ expectations of $3.57 billion. Shire PLC had a return on equity of 14.81% and a net margin of 1.62%. The business’s quarterly revenue was up 108.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.24 EPS. Equities research analysts anticipate that Shire PLC will post $12.93 EPS for the current fiscal year.
A number of research firms recently commented on SHPG. Piper Jaffray Cos. set a $201.00 price target on Shire PLC and gave the company a “hold” rating in a research report on Saturday, October 1st. Leerink Swann reissued a “buy” rating on shares of Shire PLC in a research report on Saturday, October 1st. RBC Capital Markets reissued an “outperform” rating on shares of Shire PLC in a research report on Wednesday, August 3rd. Jefferies Group reissued a “buy” rating on shares of Shire PLC in a research report on Wednesday, August 17th. Finally, TheStreet lowered Shire PLC to a “hold” rating in a research report on Thursday, August 4th. Four research analysts have rated the stock with a hold rating and twenty-three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $222.06.
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.